In short
Clinical trials are investigating Gsk3915393 in people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. These studies aim to evaluate how well Gsk3915393 works and how safe it is, mainly in adults with IPF. The main trial listed is a phase 2 study comparing Gsk3915393 with placebo.
Key points
- Clinical trials of Gsk3915393 are studying idiopathic pulmonary fibrosis, also called IPF, which is a lung disease that causes scarring. The main trial in the source is a phase 2 study with 150 participants. It compares Gsk3915393 with a placebo that matches the tablet. The main goal is to see whether Gsk3915393 can reduce the decline in lung volume, measured by forced vital capacity. The study also evaluates safety.
Clinical trial overview
The available clinical trial data show one study of Gsk3915393 in people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and can make breathing harder over time.
This study is a phase 2 trial, which means it is testing whether the treatment may help and continuing to check safety in a group of patients with the disease.
The study is listed as completed and included 150 participants.
Study design and treatment groups
The trial is an interventional study, which means researchers gave a study treatment and then measured what happened.
Participants were assigned to receive either Gsk3915393 or a placebo that matched the tablet.
A placebo looks like the study medicine but does not contain the active treatment, so it helps researchers compare results in a fair way.
Who can participate
The study was designed for participants with idiopathic pulmonary fibrosis.
The source data do not provide more detailed entry rules, such as age limits, lung test requirements, or other medical conditions that were allowed or excluded.
What the trial measures
The main outcome was the absolute change from baseline in FVC (mL) at Week 26.
FVC, or forced vital capacity, is the amount of air a person can breathe out strongly after taking a deep breath.
Baseline means the starting measurement before treatment begins, and Week 26 is the study visit after 26 weeks of treatment and follow-up.
The brief study summary says the main goal was to see whether Gsk3915393 could reduce the decline in lung volume in people with IPF compared with placebo.
What these results mean for patients
This trial focused on whether Gsk3915393 may help protect lung function in people living with IPF.
Because the study was phase 2, it was designed to learn more about possible benefit and safety rather than to give a final answer for routine care.
Only one trial was provided in the source data, so the current trial picture for Gsk3915393 is limited to this completed study in IPF.